Could multiple myeloma patients get their infusions at home?

NCT ID NCT05511428

Completed Symptom relief Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving Darzalex Faspro (a drug for multiple myeloma) at home is practical and satisfactory for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The main goal was to measure treatment satisfaction using a questionnaire. The study also tracked how well patients stuck to their home treatment schedule.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab and hyaluronidase (Darzalex Faspro)
What this could lead to: If successful, this could show that giving multiple myeloma treatment at home is safe and satisfactory, reducing the need for frequent hospital visits.
What could go wrong: This was a very small study (20 people) with no comparison group, so results may not apply to everyone. It focused on satisfaction, not on whether the drug works better or worse at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA

Contacts and locations

Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.